On September 1, 2021 Geron Corporation (Nasdaq: GERN) reported that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences (Press release, Geron, SEP 1, 2021, View Source [SID1234587096]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Virtual Investment Conference on Monday, September 13, 2021 at 7:00 a.m. ET.
R.W. Baird 2021 Virtual Global Healthcare Conference on Tuesday, September 14, 2021 at 2:00 p.m. ET.
2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 3:20 p.m. ET.
A live webcast of each presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentations, the webcasts will be archived and available for replay for a period of 30 days.

On September 1, 2021 NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, reported that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13 to 15 (Press release, NeuBase Therapeutics, SEP 1, 2021, View Source [SID1234587095]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Investment Conference
Date: Monday, September 13th
Time: 7:00 a.m. ET
Location: Webcast link or at the company’s website.

On September 1, 2021 Exelixis, Inc. (Nasdaq: EXEL) reported that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in September (Press release, Exelixis, SEP 1, 2021, View Source [SID1234587094]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 19th Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:15pm EDT / 10:15am PDT on Thursday, September 9, 2021.
H.C. Wainwright 23rd Annual Global Investment Conference: Exelixis’ pre-recorded session will be available on-demand beginning 7:00am EDT / 4:00am PDT on Monday, September 13, 2021.
BofA Securities Global Healthcare Conference: Exelixis is scheduled to present at 5:35pm BST / 12:35pm EDT / 9:35am PDT on Wednesday, September 15, 2021.
Cantor 2021 Virtual Global Healthcare Conference: Exelixis is scheduled to present at 2:40pm EDT / 11:40am PDT on Wednesday, September 29, 2021.
To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

On September 1, 2021 Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), reported that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences (Press release, Ziopharm, SEP 1, 2021, View Source [SID1234587093]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 Wells Fargo Virtual Healthcare Conference
Date: September 9, 2021
Presentation Time: 10:00 am EDT

Morgan Stanley 19th Annual Global Healthcare Conference
Date: September 10, 2021
No presentation – management available for one-on-one meetings

H.C. Wainwright 23rd Annual Global Investment Conference
Date: September 13, 2021
Time: 7:00 am EDT (access to on demand webcast begins)

Lake Street 5th Annual Best Ideas Growth Conference
Date: September 15, 2021
No presentation – management available for one-on-one meetings

2021 Cantor Virtual Global Healthcare Conference
Date: September 28, 2021
Presentation Time: 3:20 pm EDT

"As one of my initial priorities as CEO, I seek to meet with our existing shareholders and hearing their perspectives," said Mr. Boyle. "I also welcome the opportunity to introduce Ziopharm’s cutting-edge TCR science to potential new investors."

To access the webcast presentations, or the subsequent archived recordings, please see the links above or visit the "Investors" section of the Ziopharm website at www.ziopharm.com.

On September 1, 2021 Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, reported that it will report financial results for the first quarter of fiscal year 2022 on September 8, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, SEP 1, 2021, View Source [SID1234587092]). Members of Avid’s senior management will discuss financial results for the first quarter and review recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.